The cyclophilin inhibitor CRV431 prevents both HBx-cyclophilin complex formation and HBV replication
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
R. FOSTER1, D. URE1, D. TREPANIER1, P. GALLAY2
1 Contravir Pharmaceuticals Inc, Edison, New Jersey, USA and Edmonton, Alberta, Canada
2 The Scripps Research Institute, La Jolla, California, USA
